Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
One of the most notorious Mexican drug lords still at large has been captured by soldiers at a seafood restaurant in a picturesque town.
A dossier of online abuse directed at the parents of Madeleine McCann is being examined by police.
World leaders meet in London to tackle the Ebola outbreak in west Africa which has so far claimed at least 3,000 lives.